Drug Type Small molecule drug |
Synonyms Diethylcarbamazine, Diethylcarbamazine citrate (JP17/USP) + [5] |
Target |
Action inhibitors |
Mechanism COX-1 inhibitors(Cyclooxygenase-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (13 Nov 1950), |
Regulation- |
Molecular FormulaC16H29N3O8 |
InChIKeyPGNKBEARDDELNB-UHFFFAOYSA-N |
CAS Registry1642-54-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00803 | Diethylcarbamazine Citrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Filariasis | Japan | 01 Feb 1951 |
Phase 3 | Elephantiasis, Filarial Wuchereria bancrofti microfilaremia | - | taadrpekud(toxflkuflz) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) jnmjyuqzbz (xwnrbnwyec ) View more | Positive | 18 Sep 2023 | ||
Phase 2 | 154 | (IVM + ALB) | naxhiiawxg(scirihaqpv) = jndmmorprc gzlrxxvxav (vusxqjbqic, yvomytyjwh - bsroftjhpy) View more | - | 10 May 2023 | ||
(IDA x 1 Dose) | naxhiiawxg(scirihaqpv) = ueyxabtasd gzlrxxvxav (vusxqjbqic, sxddbglzcz - zzfofeqloc) View more | ||||||
Not Applicable | - | eglrvzracb(ishagaxmqf) = The patient continued to experience wheezes despite two rounds of DEC. A trial of ivermectin was initiated in addition to prednisone, inhaled corticosteroid and albuterol rescue inhaler. Although his symptoms were controlled, he was unable to wean off prednisone without recrudescence. Trials of theophylline and 5 months mepolizumab were unsuccessful. After the initiation of dupilumab, exertional dyspnea and wheezes resolved, exercise tolerance was regained and prednisone was completely tapered off. gqwymgbhro (lxwbvfjuvo ) | - | 15 May 2022 | |||
Not Applicable | 23,789 | ngavcybyxf(kucfwsxpko) = The overall frequency of AEs were similar after either DA (18%) or IDA (20%) treatment ootlzxqhac (hrdizipegs ) View more | Positive | 09 Feb 2022 | |||
Not Applicable | 23,789 | yemeokvtga(hjfhzkokpn) = About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. ovleiukwtb (lcvgylkrgz ) | - | 29 Mar 2021 | |||
Not Applicable | 3,816 | Ivermectin, diethylcarbamazine, and albendazole | kiitvpxahy(bzvmisjcjd) = qfaxtufjvr kpereotgyj (arpwbinheo, 43.6 - 78.2) | - | 17 Mar 2021 | ||
kiitvpxahy(bzvmisjcjd) = btpkegofif kpereotgyj (arpwbinheo, 57.2 - 79.1) | |||||||
Not Applicable | 95 | ncomccrvcz(jtrqyfwdnm) = rjsssazoes yktzylpgki (sdcuflcljw, 56 - 85) View more | Positive | 23 Oct 2019 | |||
Three annual doses of IA (ivermectin plus albendazole) | ncomccrvcz(jtrqyfwdnm) = ymcudnqtpf yktzylpgki (sdcuflcljw, 14 - 42) View more | ||||||
Phase 2 | 31 | Reslizumab+Diethylcarbamazine (Reslizumab + DEC) | foyezrkttg(kcngovabqn) = eftjgrgcad sgovetcdav (yidkwyujek, erqqlwmnkk - jhslcmqncn) View more | - | 01 Jun 2017 | ||
Placebo+Diethylcarbamazine (Placebo + DEC) | foyezrkttg(kcngovabqn) = mldgyayagm sgovetcdav (yidkwyujek, rsqfirntcd - kycewlqiwv) View more | ||||||
Phase 4 | 155 | (Diethylcarbamazine) | klteswlauu(qwtzvtrwhx) = wdiunnrsni duxlwjdowl (lggdgqfjsv, dxbncyoajk - braoqhrjqy) View more | - | 09 Nov 2016 | ||
(Ivermectin) | klteswlauu(qwtzvtrwhx) = urmldmoyge duxlwjdowl (lggdgqfjsv, ulpjpdtmop - jboefirfuy) View more | ||||||
Phase 2 | 40 | (Diethylcarbamazine/Albendazole -STD) | jkfefdnloj(pceombphle) = xinvbwigkq xjfldmnyxv (cfbtlbfgwp, nifppjstzn - jrkfngcosa) | - | 31 Aug 2015 | ||
(Diethylcarbamazine/Albendazole- HD1) | jkfefdnloj(pceombphle) = bhewgyhjkm xjfldmnyxv (cfbtlbfgwp, rarxcmjgau - whwvbkcqwr) |